SCHEMBL2471820

SCHEMBL2471820

CCCNS(=O)(=O)C(NC(=O)c1ccccc1OC)C1(c2ccccc2)CCNCC1

nearest known ligand 0.44

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 15/20 0.44
SLC6A9 P48067 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HPGD P15428 1/20 0.41
CTSD P07339 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2699894 0.93 ALDH1A1 (0.44) KCNA3SLC6A9ALDH1A1MEN1KMT2A
SCHEMBL4403843 0.92 ALDH1A1 (0.42) KCNA3SLC6A9ALDH1A1MEN1KMT2A
SCHEMBL2465850 0.89 HPGD (0.47) KCNA3SLC6A9ALDH1A1MEN1KMT2A
SCHEMBL2470787 0.88 ALDH1A1 (0.42) KCNA3SLC6A9ALDH1A1MEN1KMT2A
SCHEMBL2469730 0.88 ALDH1A1 (0.45) KCNA3SLC6A9ALDH1A1MEN1KMT2A
SCHEMBL2467857 0.88 ALDH1A1 (0.45) KCNA3SLC6A9ALDH1A1MEN1KMT2A
SCHEMBL2472137 0.87 KCNA3 (0.43) KCNA3SLC6A9ALDH1A1MEN1KMT2A
SCHEMBL2471700 0.87 KCNA3 (0.45) KCNA3SLC6A9ALDH1A1MEN1KMT2A
SCHEMBL2469420 0.87 KCNA3 (0.45) KCNA3SLC6A9ALDH1A1MEN1KMT2A
SCHEMBL2471134 0.86 HPGD (0.41) KCNA3SLC6A9ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function LLOYD JOHN 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function KCNJ2, KCNH2, KCNQ5 KCNA3 33/4885SLC6A9 2351/4885ALDH1A1 3941/4885
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 KCNA3 33/4885SLC6A9 2351/4885ALDH1A1 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.